Literature DB >> 22001713

Rare, unusual, and less common virus infections after organ transplantation.

Raymund R Razonable1.   

Abstract

PURPOSE OF REVIEW: The present article reviews the epidemiology, clinical presentation, prevention, and management of rare, unusual, and less common viruses that infect transplant recipients. RECENT
FINDINGS: Infection may be acquired as a result of natural transmission, reactivation of latent virus, or transmission through the allograft or blood transfusion. The epidemiology, clinical manifestations, and management of these viruses vary widely. Some viruses such as human herpesviruses 6 and 7 are ubiquitous in humans, but they rarely cause clinical disease after organ transplantation. Likewise, adenoviruses, parvoviruses, and some polyomaviruses are commonly transmitted infections in the community, but they cause clinical syndromes rarely in transplant recipients. Other viruses, such as human herpesvirus 8 and hepatitis E virus, are geographically restricted, and cause clinical disease mainly in areas of endemicity. Arenaviruses, including lymphocytic choriomeningitis virus, and rabies virus are two rare viral infections that could be transmitted through transplantation, and they cause an almost invariably fatal illness. Diagnosis of these infections is often delayed as these rare and uncommon viruses are not often considered during the initial stages of clinical investigation. Treatment almost invariably includes reductions in immunosuppression as a result of lack of effective antiviral drugs for most of these viruses.
SUMMARY: Transplant recipients are predisposed to develop severe and occasionally fatal clinical illness because of a variety of rare, unusual, and less common viruses. To optimize treatment and outcomes, these pathogens should be considered early on as potential causes of viral syndromes in transplant recipients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22001713     DOI: 10.1097/MOT.0b013e32834cdaf2

Source DB:  PubMed          Journal:  Curr Opin Organ Transplant        ISSN: 1087-2418            Impact factor:   2.640


  7 in total

1.  Rabies after lung transplantation: Existed evidence.

Authors:  Somsri Wiwanitkit; Viroj Wiwanitkit
Journal:  J Thorac Dis       Date:  2012-06-01       Impact factor: 2.895

2.  Risk of congenital cytomegalovirus infection among HIV-exposed uninfected infants is not decreased by maternal nelfinavir use during pregnancy.

Authors:  Soren Gantt; Erin Leister; Denise L Jacobsen; Isabelle Boucoiran; Meei-Li Huang; Keith R Jerome; Gonzague Jourdain; Nicole Ngo-Giang-Huong; Sandra Burchett; Lisa Frenkel
Journal:  J Med Virol       Date:  2015-11-18       Impact factor: 2.327

Review 3.  Prevalence of Kaposi's sarcoma-associated herpesvirus among intravenous drug users: a systematic review and meta-analysis.

Authors:  Qiwen Fang; Zhenqiu Liu; Zhijie Zhang; Yan Zeng; Tiejun Zhang
Journal:  Virol Sin       Date:  2017-10-13       Impact factor: 4.327

4.  Structure of the LCMV nucleoprotein provides a template for understanding arenavirus replication and immunosuppression.

Authors:  Brandyn R West; Kathryn M Hastie; Erica Ollmann Saphire
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2014-05-30

Review 5.  Role of lymphocytic choriomeningitis virus (LCMV) in understanding viral immunology: past, present and future.

Authors:  Xin Zhou; Srividya Ramachandran; Margaret Mann; Daniel L Popkin
Journal:  Viruses       Date:  2012-10-29       Impact factor: 5.048

Review 6.  Envelope glycoprotein of arenaviruses.

Authors:  Dominique J Burri; Joel Ramos da Palma; Stefan Kunz; Antonella Pasquato
Journal:  Viruses       Date:  2012-10-17       Impact factor: 5.048

7.  Probable Rabies Virus Transmission through Organ Transplantation, China, 2015.

Authors:  Hang Zhou; Wuyang Zhu; Jun Zeng; Jianfeng He; Kai Liu; Yu Li; Shuwu Zhou; Di Mu; Kechun Zhang; Pengcheng Yu; Zhijian Li; Meng Zhang; Xueqiong Chen; Chun Guo; Hongjie Yu
Journal:  Emerg Infect Dis       Date:  2016-08-15       Impact factor: 6.883

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.